Ctt Pharmaceutic Financials

No, Ctt Pharmaceutic (CTTH) reported a net income of -$672K in fiscal year 2015.

Ctt Pharmaceutic (CTTH) reported diluted earnings per share of $0.01 for fiscal year 2015. This represents a 109.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ctt Pharmaceutic (CTTH) has a return on equity of -45.0% for fiscal year 2015, measuring how efficiently the company generates profit from shareholder equity.

Ctt Pharmaceutic (CTTH) generated -$72K in operating cash flow during fiscal year 2015, representing cash generated from core business activities.

Ctt Pharmaceutic (CTTH) had $1.7M in total assets as of fiscal year 2015, including both current and long-term assets.

Ctt Pharmaceutic (CTTH) had 20M shares outstanding as of fiscal year 2015.

Ctt Pharmaceutic (CTTH) had a current ratio of 0.03 as of fiscal year 2015, which is below 1.0, which may suggest potential liquidity concerns.

Ctt Pharmaceutic (CTTH) had a debt-to-equity ratio of 0.11 as of fiscal year 2015, measuring the company's financial leverage by comparing total debt to shareholder equity.

Ctt Pharmaceutic (CTTH) had a return on assets of -40.4% for fiscal year 2015, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2015 data, Ctt Pharmaceutic (CTTH) had $81K in cash against an annual operating cash burn of $72K. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Ctt Pharmaceutic (CTTH) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Ctt Pharmaceutic (CTTH) has an earnings quality ratio of 0.11x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.